Abstract:

Objective　To study on the laboratory solutions for ethylenediaminetetraacetic acid（EDTA）-dependent pseudothrombocytopenia. Methods　A total of 5 patients with EDTA-dependent pseudothrombocytopenia were enrolled， and each blood with EDTA-K₂ anticoagulant was added to 6.5 mg/mL amikacin in different time periods. The blood routine test and blood smears were performed. Results　In 3 patients before collecting blood or collecting blood after 1.5h， its inherent EDTA anticoagulant was added amikacin， which can not affect the situation of other blood cell morphology and distribution of dissociation platelet aggregation， and the platelet count can be stable within 4h at room temperature. In the other 2 patients， with or without amikacin， the platelet count increased gradually with time and eventually returned to normal levels， and amikacin played acceleration role. Conclusions　The test results of platelet adding amikacin in 4h are stable and reliable， and the drug use of antibiotics in hospitals is general. In clinical practice， it can reduce the duplication of collecting blood and shorten turn-around-time. Amikacin should be as first-line approach in the treatment of EDTA-dependent pseudothrombocytopenia.

Key words: Pseudothrombocytopenia, Anticoagulant, Amikacin